El Lilly’s Olomorasib Shows Durable, Chemotherapy‑Free Control in KRAS G12C Lung Cancer
Early‑phase data reveal Eli Lilly’s KRAS G12C inhibitor, olomorasib, delivers durable, chemo‑free control in NSCLC and shows promise in a Phase III trial.
3 minutes to read

